References to studies used to describe the risks of recurrent venous thromboembolism (VTE) in individuals with a thrombophilic defect as compared to individuals with a first episode of VTE without a thrombophilic defect.
| Thrombophilic Defect . | Estimated Relative Risk . | References . |
|---|---|---|
| * pooled using the using the Mantel-Haenszel method | ||
| Antithrombin, protein C, or protein S deficiency | 2.5 | De Stefano V.
Thromb Haemost . 1994 ;72 :352 –358.Van den Belt AG.
Arch Int Med . 1997 ;157 :2227 –2232.Margaglione M. Thromb Haemost . 1999 ;82 :1583 –1587. |
| Factor V Leiden mutation | 1.4* | Lindmarker P.
Thromb Haemost . 1999 ;81 :684 –689.Simioni P.
N Eng J Med . 1997 ;336 :399 –403.Ridker PM.
Circulation 1995 ;92 :2800 –2802.Eichinger S.
Arch Intern Med 2002 ;162 :2357 –2360.Rintelen C.
Thromb Haemost . 1996 ;75 :229 –232.Baglin T.
Lancet 2003 ;362 :523 –526.Palareti G. Circulation 2003 ;108 :313 –318. |
| Prothrombin 20210A mutation | 1.4* | Lindmarker P.
Thromb Haemost . 1999 ;81 :684 –689.Baglin T.
Lancet 2003 ;362 :523 –526.Eichinger S.
Thromb Haemost . 1999 ;81 :14 –17.De Stefano V.
Br J Haematol . 2001 ;113 :630 –635.Miles JS. J Am Coll Cardiol . 2001 ;37 :215 –218. |
| Elevated levels of factor VIII:c | 6–11 | Kraaijenhagen RA.
Thromb Haemost . 2000 ;83 :5 –9.Kyrle PA.
N Eng J Med . 2000 ;343 :457 –462.Legnani C. Br J Haematol . 2004 ;124 :504 –510. |
| Mild hyperhomocysteinemia | 2.6–3.1 | Den Heijer M.
Lancet . 1995 ;345 :882 –885.Eichinger S. Thromb Haemost . 1998 ;80 :566 –569. |
| Antiphospholipid antibodies | 2–9 | Prandoni P.
Thromb Haemost . 1996 ;75 :859 .Rance A.
Thromb Haemost . 1997 ;77 :221 –222.Schulman S. Am J Med . 1998 ;104 :332 –338. |
| Thrombophilic Defect . | Estimated Relative Risk . | References . |
|---|---|---|
| * pooled using the using the Mantel-Haenszel method | ||
| Antithrombin, protein C, or protein S deficiency | 2.5 | De Stefano V.
Thromb Haemost . 1994 ;72 :352 –358.Van den Belt AG.
Arch Int Med . 1997 ;157 :2227 –2232.Margaglione M. Thromb Haemost . 1999 ;82 :1583 –1587. |
| Factor V Leiden mutation | 1.4* | Lindmarker P.
Thromb Haemost . 1999 ;81 :684 –689.Simioni P.
N Eng J Med . 1997 ;336 :399 –403.Ridker PM.
Circulation 1995 ;92 :2800 –2802.Eichinger S.
Arch Intern Med 2002 ;162 :2357 –2360.Rintelen C.
Thromb Haemost . 1996 ;75 :229 –232.Baglin T.
Lancet 2003 ;362 :523 –526.Palareti G. Circulation 2003 ;108 :313 –318. |
| Prothrombin 20210A mutation | 1.4* | Lindmarker P.
Thromb Haemost . 1999 ;81 :684 –689.Baglin T.
Lancet 2003 ;362 :523 –526.Eichinger S.
Thromb Haemost . 1999 ;81 :14 –17.De Stefano V.
Br J Haematol . 2001 ;113 :630 –635.Miles JS. J Am Coll Cardiol . 2001 ;37 :215 –218. |
| Elevated levels of factor VIII:c | 6–11 | Kraaijenhagen RA.
Thromb Haemost . 2000 ;83 :5 –9.Kyrle PA.
N Eng J Med . 2000 ;343 :457 –462.Legnani C. Br J Haematol . 2004 ;124 :504 –510. |
| Mild hyperhomocysteinemia | 2.6–3.1 | Den Heijer M.
Lancet . 1995 ;345 :882 –885.Eichinger S. Thromb Haemost . 1998 ;80 :566 –569. |
| Antiphospholipid antibodies | 2–9 | Prandoni P.
Thromb Haemost . 1996 ;75 :859 .Rance A.
Thromb Haemost . 1997 ;77 :221 –222.Schulman S. Am J Med . 1998 ;104 :332 –338. |